As part of a collaborative endeavor, we will work together to develop a customized antibody discovery strategy employing Immune Biosolutions’ highly flexible Nebula Antibody Platform. With this tailored plan (which includes pre-defined and appropriate inflection milestones and success criteria), we can expect a significantly de-risked discovery phase.

To create a set of preclinical-ready candidates, Immune Biosolutions will undertake research and development activities in accordance with our discovery strategy, including for instance:

· Design and synthesis of antigenic Spatial Peptides

· Development of a large panel of humanized chicken antibodies (50-200 antibody library) against the desired target

Immune Biosolutions strives for continued communication and collaboration with our partners to ensure that our discovery-phase milestones and timelines are met and to allow for iterative design and optimization as candidates enter preclinical and clinical validation.